Last Updated:
Wockhardt Ltd announced its financial results for FY2024-25, reporting a strong 67% year-on-year growth in EBITDA.
Wockhardt Ltd shares are in focus.
Rekha Jhunjhunwala Portfolio: Wockhardt Ltd’s shares, a pharma company, zoomed 17 per cent intraday on Wednesday to touch its 52-week high of Rs 1,810.45 apiece. There’s a sharp surge in trading volume of Wockhardt Ltd’s shares. A total of 5.10 crore equities have exchanged hands so far.
Looking at the long horizon of over one month, shares have gained almost 43 per cent, giving a good return to investors.
Wockhardt Limited Ltd is in smallcap index and has a market cap of Rs 29,342 crore as of June 11.
The stock’s 52-week high and low reflect Rs 1,815.20 and Rs 552.20 apiece on BSE.
The stock has turned a gold mine for investors with multifold returns in the past few years. The stock is up 42 per cent in one month. In the past one year, the stocks have given a return of 207 per cent as per BSE analytics. Over the two year phase, the returns grew to 950 per cent.
According to BSE public shareholder information, Rekha Jhunjhunwala holds 28,37,005 equity shares, representing 1.75 per cent stakes in Wockhardt Ltd.
Founded in the 1960s by Dr. Habil Khorakiwala and headquartered in Mumbai, Wockhardt Ltd is a global pharmaceutical and biotechnology player. It manufactures finished dosages, APIs, biosimilars, vaccines, and operates hospitals through Wockhardt Hospitals.
Wockhardt Q4 Results
Wockhardt Ltd announced its financial results for FY2024-25, reporting a strong 67% year-on-year growth in EBITDA. For the full year, EBITDA rose to Rs 418 crore, up from Rs 251 crore in the previous year. The company’s revenue also registered a modest 5% increase, reaching Rs 3,033 crore compared to Rs 2,879 crore in FY24.
In Q4 FY25, the company posted revenue of Rs 743 crore, slightly lower than Rs 750 crore in the same quarter last year. However, EBITDA for the quarter showed a sequential improvement, rising 13% quarter-on-quarter to Rs 79 crore from Rs 70 crore in Q3 FY25.
Wockhardt also shared key regulatory milestones for its specialty drugs. The company filed for approval of its novel antibiotic Zaynich in India in March 2025 and plans to file for US approval by August. Another antibiotic, Miqnaf, received regulatory approval in India and was officially launched on May 27, 2025, marking a major step in the company’s pivot toward high-value specialty products.
Varun Yadav is a Sub Editor at News18 Business Digital. He writes articles on markets, personal finance, technology, and more. He completed his post-graduation diploma in English Journalism from the Indian Inst…Read More
Varun Yadav is a Sub Editor at News18 Business Digital. He writes articles on markets, personal finance, technology, and more. He completed his post-graduation diploma in English Journalism from the Indian Inst… Read More
- First Published:
